Application of Cetrorelix - A GnRH-antagonist in reproductive medicine;Zum einsatz des GnRH-antagonisten Cetrorelix in der reproduktionsmedizin

Geburtshilfe und Frauenheilkunde

Volumn 60, Issue 4, 2000, Pages 212-217

  Keck, C ^a   Felberbaum, R ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Univ Frauenklinik Lübeck   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; LUTEINIZING HORMONE;

ARTICLE; FEMALE; HUMAN; LUTEINIZING HORMONE RELEASE; OVARY HYPERSTIMULATION; PREGNANCY RATE; REPRODUCTION;

EID: 0034030676     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Albano C, Grimbizis G, Smitz J, Riethmüller-Winzen H, Reissmann T, van Steirteghem A, Devroey P. The luteal phase of non-supplemented cycles after ovarian superovulation with the human menopausal gonadotrophin and the gonadotrophin-releasing hormone antagonist cetrorelix. Fertil Steril 1998; 70: 357-359
2. Albano C, Smitz J, Camus M, Riethmüller-Winzen H, van Steirteghem A, Devroey P. Comparison of different doses of gonadotrophin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997; 67: 917-922
3. Albano C, Smitz J, Tournaye H, Riethmüller-Winzen H, van Steirteghem A, Devroey P. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmatic sperm injection cycles. Hum Reprod 1999; 14: 1426-1430
4. Albano C, Felberbaum RE, Smitz J, Riethmüller-Winzen H, Engel J, Diedrich K, Devroey P. Controlled ovarian stimulation with hMG: results of a prospective randomized phase III European study comparing the LHRH-antagonist Cetrorelix (Cetrotide) and the LHRH-agonist Buserelin (in press)
5. Bouchard P, Caraty A, Medalie D, et al. Mechanisms of action and clinical uses of GnRH-antagonists in women. In: Bouchard P, Haour F, Franchimont P, Schatz B (eds). Recent progress on GnRH and gonadal peptides. Paris: Elsevier; 1990: 209-219
6. Diedrich K, Diedrich C, Santos E, Zoll C, Al-Hasani S, et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994; 9: 788-791
7. Felberbaum R, Diedrich K. Ovulation induction, Update '98. In: Filicori M, Flamigni C (eds). Carnforth: Parthenon Publishing Group; 1998: 121-131
8. Felberbaum R, Reissmann T, Diedrich K. Entwicklung und Anwendungsmöglichkeiten der GnRH-Antagonisten im Rahmen der Sterilitätstherapie. Fertilität 1995; 11: 11-21
9. Felberbaum R, Reissmann T, Küpker W, et al. Hormone profiles under ovarian stimulation with human menopausal gonadotrophin (hMG) and concomitant administration of the gonadotrophin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages. J Assist Reprod Genet 1996; 13: 216-222
10. Felberbaum R, Albano C, Ludwig M, Riethmüller-Winzen H, Grigat M, Devroey P, Diedrich K. Controlled ovarian stimulation for assisted reproduction with hMG and concomitant midcycle administration of the LHRH-antagonist Cetrorelix (Cetrotide®) according to the multiple dose protocol-results of a prospective non controlled phase III study. Hum Reprod (in press)
11. Fleming R. Induction of multiple follicular growth in normally menstruating women with endogenous gonadotrophin suppression. Fertil Steril 1986; 45(2): 226-230
12. Hamm W. Cetrorelix Multidose protocol: results of the largest multinational study with an antagonist in ART. Middle East Fertility Society Journal 1999; 4 (Suppl 3): 24-25
13. Hugues JN, Cedrin-Durnerin I, Bstandig B, Blasquez M, Hervé F, Uzan M. Comparison of recombinant and urinary follicle stimulating hormone preparations efficacy for achievement of follicular selection in patients with chronic anovulation (WHO group II). Human Reprod 1999; 14 (Abstract Book 1): 127-128
14. Klingmüller D, Schepke M, Enzweiler C, Bidlingmaier F. Hormonal responses to the new potent GnRH Antagonist Cetrorelix. Acta Endocrinol 1993; 128: 15-18
15. Loumaye E. The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in vitro fertilization and embryo transfer. Hum Reprod 190; 5: 357-376
16. Ludwig M, Felberbaum R, Albano C, Olivennes F, Riethmüller-Winzen H, Devroey P, Diedrich K. Cetrorelix levels in plasma and follicular fluid. Gynecol Endocrinol 1999; 13 (Suppl 1): Abstr. 30
17. Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R. The use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 vs. 2 mg. Hum Reprod 1998; 13 (9): 2411-2413
18. Olivennes F, Belaisch-Allart J, Emperaire JC, Hedon B, Alvarez S, Moreau L, Nicollet B, Zorn JR, Bouchard P, Frydman R. Comparison in a prospective multicentric randomized study in IVF-ET of a single dose of GnRH antagonist (Cetrorelix) to a GnRH agonist long protocol (Triptoreline in depot formula). Gynecol Endocrinol 1999; 13 (Suppl 1): Abstr 27
19. Penzias AS. Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: a randomized clinical trial. Obstet Gynecol 1992; 79 (5): 739-742
20. Riethmuller-Winzen H, Siebert-Weigel M, Prothmann A. Safety aspects of GnRH Antagonists. Gynecol Endocrinol 1999; 13 (Suppl 1): 50
21. Ron-El R. Improved pregnancy rate in IVF/ET by combined long-acting GnRH-Analogue and gonadotrophin. In: Vickery BH, Lunenfeld B (eds). GnRH-Analogues in Reproduction and gynecology. Dordrecht: Kluwer Academic Publishers 1990; Vol II, Chapter 18: 167-171
22. Rongières-Bertrand C, Olivennes F, Bouchard P, Frydman R. Clinical use of GnRH antagonists in in-vitro Fertilization: single dose protocols. In: Filicori M, Flamigni C (eds). Ovulation induction Update'98. Carnforth: Parthenon Publishing Group; 1998: 133-136
23. Rongières-Bertrand C, Olivennes F, Righini C, Fanchin R, Hamamah S, Bouchard P, Frydman R. Revival of the natural cycles in in-vitro-fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum Reprod 1999; 14: 683-688
24. Smitz J, Devroey P, Camus M, Deschacht J, Khan I, Staessen C, et al. The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF and GIFT. Hum Reprod 1998; 3: 585-590
25. Sommer L, Zanger K. Dyong T, Dorn C, Luckhaus J, Diedrich K, Klingmüller D. Seven-day administration of the gonadotrophin-releasing hormone antagonist Cetrorelix in normal cycling women. Eur J Endocrinol 1994; 131: 280-285
26. Stanger JD, Yovich JL. Reduced in-vitro fertilization of human oocytes from parents with raised basal luteinizing hormone levels during the follicular phase. Br J Obstet Gynecol 1985; 92: 385-393
27. Strowitzki T. Wenn das Wunschkind ausbleibt: Ursachen, Diagnose und Behandlungsmöglichkeiten. Heidelberg: Hüthig; 1998